Expand XLO Menu
XLO MENU

XLO Latest Press Releases

-- November 13, 2025 --

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results Globe Newswire 7:30 AM

-- November 7, 2025 --

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting Globe Newswire 9:05 AM
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting Globe Newswire 9:01 AM

-- November 3, 2025 --

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- October 30, 2025 --

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting Globe Newswire 9:01 AM

-- October 3, 2025 --

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting Globe Newswire 9:00 AM

-- October 2, 2025 --

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- September 9, 2025 --

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead Globe Newswire 7:30 AM

-- August 14, 2025 --

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results Globe Newswire 7:30 AM

-- August 4, 2025 --

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors Globe Newswire 8:03 AM

-- August 1, 2025 --

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM
Market Data Delayed 15 Minutes